Dr. Bill Mason
B.Sc. in Biophysical Chemistry, Case Western Reserve University. PhD in Physiology and Medicine, Trinity College, University of Cambridge, UK.
Led medical research group in Cambridge for 20 years.
Founder of Life Science Resources, divested to Perkin Elmer following three key acquisitions, financing and revenue/profit growth.
NXC/NXD of a portfolio of healthcare and life science businesses, private and public with experience of IPOs and VC funding.
Experience of more than 75 healthcare transactions including divestment, M&A, licensing, funding, business development, strategic partnering.
Dr. Bill Mason heads the EU operation for Sage Group, as Executive Director of Sage Healthcare Ltd based near Cambridge, UK.
Bill gained his doctorate in medicine and physiology from Trinity College, Cambridge, in the UK. Prior to his successful business career, he led an academic program of medical research focused on neuroscience discovery and medical imaging technology. He has over 150 publications and has lectured widely around the world. He is the founder of several successful high technology companies. One of these, Life Science Resources, was sold to Perkin Elmer Life Sciences PLC, and was engaged in medical imaging and high throughput screening and drug discovery.
He has worked with a number of healthcare, life science and biotech companies to develop their strategic direction, realize funding, gain value for shareholders and implement business development, commercialization and licensing activity. In this capacity, he has conducted over 75 transactions in healthcare and life sciences in the last five years.
Dr. Mason also acts as a non-executive Chairman or Director for a portfolio of quoted and unquoted life science companies. He has led and been involved in several public flotations on the NASDAQ exchange in the USA and the London Stock Exchange. He was a founding Advisory Board Member of several venture capital funds, and works with them and other financial institutions in guiding early stage companies through growth and on to realizing value for shareholders. He has also worked in the UK Cabinet Office as part of the Advisory Council on Science and Technology (ACOST) leading strategy development for UK policy on education and science.